This indefinite delivery contract (IDC) awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Midwest Research Institute (doing business as Mriglobal) aims to provide pre-clinical evaluation of infectious disease countermeasures. The $146.3 million single-award IDC has a period of performance through August 2024. The contract covers the development and refinement of small animal, non-human primate, and animal replacement/non-traditional models to...
This indefinite delivery contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a subsidiary of the Illinois Institute of Technology. The contract has a ceiling value of $146.3 million and a period of performance through July 2031. The purpose of this IDC is to provide NIAID with a range of preclinical research services related to the development and...
This indefinite delivery contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to the American Foundation For Biological Research, doing business as the Biomedical Research Institute. The $146.3 million single-award IDC has a period of performance from July 15, 2024 to July 14, 2031. The purpose of this IDC is to provide NIAID with the capability and capacity to develop and employ...
This federal Indefinite Delivery Contract (IDC) was awarded by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services, to Mriglobal, doing business as Midwest Research Institute, a 501(c)(3) not-for-profit research organization. The $49,990,000 single-award IDC has an ultimate completion date of June 30, 2028 and does not have a set-aside designation. Under this IDC, Mriglobal is providing a range of scientific research, testing, and product...
This indefinite delivery contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to KMT Hepatech Inc., a foreign-owned for-profit organization. The $40 million, multiple-award IDC runs from July 2017 through July 2024 and covers pre-clinical models of infectious diseases. Under this IDC, the initial task order for $2,309 was issued in October 2017 for a base funding...
This indefinite delivery contract (IDC) was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a component of the U.S. Department of Health and Human Services (HHS), to Mriglobal, doing business as Midwest Research Institute, a 501(c)(3) not-for-profit research organization. The $45 million single-award IDC has a period of performance through July 31, 2025 and is for the development of animal models to evaluate the efficacy of medical countermeasures (MCMs)...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. Department of Health and Human Services, awarded a $146.3 million Indefinite Delivery Contract (IDC) to Institute For Clinical Pharmacodynamics, Inc., a for-profit organization, to provide pre-clinical models of infectious diseases under Task Area C. The period of performance is from July 15, 2024 to July 14, 2031. The contract is a follow-on to a previous Preclinical Models of Infectious Diseases...
This federal contract award is an Indefinite Delivery, Indefinite Quantity (IDIQ) contract for the Diagnostics Pre-Clinical Services Program, awarded by the Department of Health and Human Services' National Institutes of Health, National Institute of Allergy and Infectious Diseases to the prime contractor MRI Global, also doing business as Midwest Research Institute. The contract has a potential value of $24,000,000 and a period of performance through June 2030. Under this IDIQ, MRI Global...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded an $80 million Indefinite Delivery Contract (IDC) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI) for preclinical models of infectious diseases research from 2017 to 2024. LBERI, doing business as Inhalation Toxicology Research Institute, is a non-profit contract research organization that provides expertise in areas such as inhalation toxicology, infectious disease modeling, and medical...
The National Institute of Allergy and Infectious Diseases awarded a single award indefinite delivery contract to Mriglobal, doing business as Midwest Research Institute, with a potential value of $545,452,906 and period of performance from September 1, 2021 through August 31, 2028. The contract provides comprehensive and rapid response services to support NIAID's research programs including clinical trials, manufacturing, nonclinical studies, analytics, and basic research. A $2,000 firm fixed...
This federal Indefinite Delivery Contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Mriglobal (doing business as Midwest Research Institute), a 501(c)(3) not-for-profit research organization. The $40 million IDC, titled "Pre-Clinical Models of Infectious Diseases", has an ultimate completion date of July 13, 2024 and is part of the larger NIAID Preclinical Models of Infectious Diseases 2017-2024 master IDIQ contract vehicle.
Under this IDC, Mriglobal provides NIAID with a range of specialized scientific research, testing, and product development services related to medical countermeasure development, biosafety testing, threat detection technologies, and other infectious disease research capabilities. This includes analytical testing, biorepository management, pharmaceutical manufacturing, and animal studies. The contract has an initial task order valued at $5,660.01 for "BASE IDIQ TASK ORDER KICK OFF - B-01". Mriglobal frequently serves as both a prime contractor and subcontractor, partnering with universities, other research institutes, and small businesses to deliver comprehensive R&D services for federal agencies including HHS, DoD, and DHS.